<DOC>
	<DOCNO>NCT00492947</DOCNO>
	<brief_summary>This research study test new treatment cancer head neck . Purpose This research study do : 1 . Test safety experimental cancer vaccine make dendritic cell . An experimental vaccine one approve Food Drug Administration ( FDA ) . 2 . To learn effect ( good bad ) vaccine head neck cancer . 3 . To learn vaccine stimulate body 's white blood cell , part immune system ( body 's natural defense system ) .</brief_summary>
	<brief_title>Dendritic Cell Vaccine Head Neck Cancer</brief_title>
	<detailed_description>White blood cell part body 's defense system . Sometimes cancer , body know cancer cell make sick . We hope teach white blood cell find destroy cancer cell vaccine . The vaccine make special kind blood cell call dendritic cell . This cell carry information cancer white blood cell body .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Squamous cell carcinoma head neck patient unresectable recurrent disease distant metastasis patient fail conventional radiation therapy and/or chemotherapy refuse surgical salvage . Presence cervical metastasis able accessed injection Biopsy accessible tumor ( metastatic primary ) &gt; 18 year age . The following laboratory value obtain ≤14 day prior registration : ANC ≥1500 PLT ≥100,000 Hgb ≥ 9.0 g/dL Alkaline phosphatase ≤3 x UNL AST ≤3 x UNL Creatinine ≤1.5 x UNL Life expectancy ≥6 month . ECOG performance status 0 , 1 , 2 . No chemotherapy prior 4 week . Pregnant woman . Nursing woman . Men woman childbearing potential unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device { IUD } , abstinence . ) Known HIV infection . Concurrent use systemic immunosuppressant . Other immunocompromising condition opinion physician render patient poor candidate trial . Other active cancer require therapy control disease . Unwillingness return followup evaluation period 2 year follow completion protocol therapy . Other intercurrent medical problem , opinion investigator , would make participation study hazardous patient Patients otolaryngologist , radiation oncologist , medical oncologist agree consensus node treat . Patients CNS metastasis involvement sit inflammatory response would constitute immediately life threaten situation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>vaccine</keyword>
	<keyword>intra tumoral</keyword>
	<keyword>squamous cell carcinoma</keyword>
</DOC>